Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 August 2026 | Viewed by 3946

Special Issue Editors

Dr. Mariola Drozd

E-Mail Website
Guest Editor
Department of Humanities and Social Medicine, Medical University of Lublin, Lublin, Poland
Interests: pharmaceutical care; clinical pharmacy; pharmacology; pharmacoeconomic
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jakub Pawlikowski

E-Mail Website
Guest Editor
Department of Humanities and Social Medicine, Medical University of Lublin, 20-093 Lublin, Poland
Interests: ethics; bioethics; therapy; law
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue aims to highlight pharmacotherapeutic safety. Drug problems such as adverse drug reactions, drug interactions, or pharmacotherapy errors and the possibility of preventing them, detecting them, and examining recent advances in understanding their occurrence are now a challenge for medicine to ensure patient safety.

This Special Issue aims to cover the field of clinical pharmacy services as a tool for ensuring safety in pharmacotherapy.

Drug problems such as adverse drug reactions, drug interactions, dosage errors, or medication administration errors cause many clinical but also economic consequences for the patient as well as the health care system. Many of these drug problems also have ethical implications for medical personnel in particular.

Studies using clinical trials, observational studies, and advanced analytical methods to improve the safety of pharmacotherapy are welcome.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: drug-related problems, clinical pharmacy, clinical pharmacology, pharmaceutical care, pharmacotherapy, adverse drug reactions, drug interactions, and ethics in scientific research.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Medicines.

Dr. Mariola Drozd
Prof. Dr. Jakub Pawlikowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adverse drug reaction
  • drug-related problems
  • drug formulation technology
  • safety of pharmacotherapy
  • clinical pharmacy
  • pharmaceutical care
  • pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 258 KB  
Article
Clinical Outcomes and Factors Associated with Neuroleptic Malignant Syndrome in Older Patients: A Case Control Study
by Pataraporn Pewloungsawat, Sahaphume Srisuma and Sirasa Ruangritchankul
J. Clin. Med. 2025, 14(24), 8901; https://doi.org/10.3390/jcm14248901 - 16 Dec 2025
Viewed by 940
Abstract
Background/Objectives: Older adults are vulnerable to multiple neuropsychiatric diseases. Antipsychotics and dopamine agents are widely used and are associated with neuroleptic malignant syndrome (NMS). However, NMS has still received limited focus in older Thai adults. This study aimed to evaluate the factors associated [...] Read more.
Background/Objectives: Older adults are vulnerable to multiple neuropsychiatric diseases. Antipsychotics and dopamine agents are widely used and are associated with neuroleptic malignant syndrome (NMS). However, NMS has still received limited focus in older Thai adults. This study aimed to evaluate the factors associated with NMS in older Thai adults and to review the clinical manifestations, adverse outcomes, severity, preventability, and management of NMS. Methods: The case–control study was conducted on older patients aged ≥ 60 years admitted to Ramathibodi Hospital between 1 August 2008, and 31 July 2022. Data were retrieved from electronic medical record reviews. Patients with NMS were identified by the documented International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) code G21.0 or ICD-9 code 333.92. The non-NMS or control group was matched by age, sex, time of admission, and agent exposure 14 days before the index date. Results: Fifty-four older patients admitted to the hospital were enrolled in this study. Of all, nine (16.7%) were diagnosed to have NMS. The most common causes of NMS were antipsychotic exposure (6 cases). All NMS events were considered to be “preventable” (scores of 4–6) according to the Likert scale. The independent factor associated with NMS was antipsychotic dose > 1 defined daily doses (DDDs) (OR 11.31, 95% CI 1.05–121.84, p = 0.045). Conclusions: NMS is a preventable condition. Most NMS cases develop from antipsychotic exposure. In addition, a higher daily dose of antipsychotics is associated with the development of NMS. Full article
(This article belongs to the Special Issue Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy)

Review

Jump to: Research

13 pages, 556 KB  
Review
Medication Therapy Problems in Hospitalized Patients with Decreased Kidney Function Across the Spectrum of Kidney Disease: A Scoping Review
by Tomona Iso, Danielle Antwan, Melanie Galima, Monarc Manlongat, Safer Marogy, Redi Ndrekaj and Lisa Hong
J. Clin. Med. 2026, 15(7), 2606; https://doi.org/10.3390/jcm15072606 - 29 Mar 2026
Viewed by 416
Abstract
Background: This scoping review aimed to identify gaps in the literature regarding medication therapy problems (MTPs) among hospitalized adults with decreased kidney function. Specifically, it aimed to answer the following questions: (1) What types of MTPs have been reported? (2) What is [...] Read more.
Background: This scoping review aimed to identify gaps in the literature regarding medication therapy problems (MTPs) among hospitalized adults with decreased kidney function. Specifically, it aimed to answer the following questions: (1) What types of MTPs have been reported? (2) What is the reported prevalence of MTPs? (3) Do MTPs differ by type of kidney disease? (4) What gaps exist regarding MTPs and pharmacists’ involvement? Methods: Studies involving adult patients with decreased kidney function that investigated MTPs were included. Studies focused exclusively on post-transplant care, chemotherapy, or a single MTP type were excluded. Literature searches were conducted in PubMed, EMBASE, Cochrane Library, Web of Science, and International Pharmaceutical Abstracts. Two independent reviewers screened and extracted data, with a third reviewer resolving discrepancies. All identified MTPs were re-categorized using the Pharmacy Quality Alliance (PQA) framework and the Pharmaceutical Care Network Europe (PCNE) classification. Results: A total of 23 studies met the inclusion criteria, including two conference proceedings, encompassing 7151 patients. The most common MTP framework was the PCNE classification (13 studies, 57%). Reclassification using the PQA yielded 10,596 MTPs, most frequently “Safety—dosage too high” (n = 2464) and “Effectiveness—dosage too low” (n = 2262). Reclassification using the PCNE yielded 11,574 MTPs, most frequently “Drug selection” (n = 6974) and “Dose selection” (n = 2636). All studies involved patients with chronic kidney disease (CKD), and two also included acute kidney injury (AKI). Conclusions: Dosage-related MTPs were most prevalent among hospitalized patients with decreased kidney function. Variability in MTP definitions, limited representation of patients with AKI and AKD, and minimal reporting on pharmacists’ roles reveal important gaps. Addressing these gaps through standardized MTP classification and further research in understudied kidney disease populations may enhance patient safety and support clinical pharmacists’ contributions to optimizing medication safety across the kidney disease continuum. Full article
(This article belongs to the Special Issue Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy)
►▼ Show Figures

Figure 1

13 pages, 759 KB  
Review
Prevalence of Polypharmacy Among Patients with Chronic Liver Disease—A Narrative Literature Review
by Monika Szkultecka-Dębek, Lucyna Bułaś, Agnieszka Skowron and Mariola Drozd
J. Clin. Med. 2025, 14(17), 6263; https://doi.org/10.3390/jcm14176263 - 5 Sep 2025
Cited by 2 | Viewed by 2035
Abstract
Background and aim: Managing the therapy of patients with chronic liver diseases and comorbidities presents significant challenges for physicians and pharmacists, particularly regarding drug-induced liver damage and polypharmacy. Given the liver’s central role in drug detoxification, polypharmacy in liver disease requires special attention. [...] Read more.
Background and aim: Managing the therapy of patients with chronic liver diseases and comorbidities presents significant challenges for physicians and pharmacists, particularly regarding drug-induced liver damage and polypharmacy. Given the liver’s central role in drug detoxification, polypharmacy in liver disease requires special attention. The aim of the review was to assess the prevalence of polypharmacy among patients with chronic liver diseases. Approach and Results: A literature search focused on randomized controlled trials, database reviews, and medical records. Review of PubMed, SCOPUS, and ScienceDirect databases identified 2578 manuscripts, however only 11 studies met the inclusion criteria. The results of studies showed that the prevalence of polypharmacy among patients with chronic liver disease can exceed 50%, and can lead to high prevalence of MRP and pDDI among those patients. Conclusions: Findings reveal a critical link between polypharmacy and adverse outcomes in chronic liver diseases, including cirrhosis, hepatitis, and non-alcoholic fatty liver disease. Individualized treatment plans, considering factors such as age, gender, comorbidities, and liver disease severity are essential. The interventions focused on mitigating MRP and reducing pDDI need to be implemented in order to reduce the potential harm of polypharmacy. Full article
(This article belongs to the Special Issue Drug-Related Problems: Clinical Pharmacy and Safety of Pharmacotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop